NASDAQ:VYGR

Voyager Therapeutics (VYGR) Stock Forecast, Price & News

$12.05

+0.11 (+0.92%)

(As of 05/26/2023 08:48 PM ET)

Compare

Today's Range: $11.80
▼
$12.40
50-Day Range: $6.94
▼
$13.85
52-Week Range: $4.61
▼
$14.34

Volume: 519,300 shs
Average Volume: 466,027 shs
Market Capitalization: $524.66 million

P/E Ratio: 5.29
Dividend Yield: N/A
Price Target: $16.00

Voyager Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 32.8% Upside
$16.00 Price Target
Short Interest: Healthy
3.20% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.59
Upright™ Environmental Score
News Sentiment: 0.57
Based on 6 Articles This Week
Insider Trading: Selling Shares
$147,684 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From $1.01 to ($1.99) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.72 out of 5 stars

Medical Sector

78th out of 1,012 stocks

Biological Products, Except Diagnostic Industry

11th out of 169 stocks

3.5

Analyst's Opinion

Consensus Rating
Voyager Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $16.00, Voyager Therapeutics has a forecasted upside of 32.8% from its current price of $12.05.
Amount of Analyst Coverage
Voyager Therapeutics has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.20% of the float of Voyager Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Voyager Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Voyager Therapeutics has recently increased by 7.84%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Voyager Therapeutics does not currently pay a dividend.
Dividend Growth
Voyager Therapeutics does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Voyager Therapeutics has received a 77.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Voyager Therapeutics is -0.59.

3.1

News and Social Media Coverage

News Sentiment
Voyager Therapeutics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Voyager Therapeutics this week, compared to 4 articles on an average week.
Search Interest
10 people have searched for VYGR on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.
MarketBeat Follows
4 people have added Voyager Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Voyager Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $147,684.00 in company stock.
Percentage Held by Insiders
22.00% of the stock of Voyager Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
59.58% of the stock of Voyager Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Voyager Therapeutics are expected to decrease in the coming year, from $1.01 to ($1.99) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Voyager Therapeutics is 5.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 134.72.
Price to Earnings Ratio vs. Sector
The P/E ratio of Voyager Therapeutics is 5.29, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 133.04.
Price to Book Value per Share Ratio
Voyager Therapeutics has a P/B Ratio of 2.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Voyager Therapeutics (NASDAQ:VYGR) Stock

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.

Receive VYGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VYGR Stock News Headlines

May 27, 2023 | msn.com

Newshub, Lisette Reymer, Karen Rutherford win at 2023 Voyager Media Awards

May 27, 2023 | msn.com

RNZ takes home several top Voyager Media Awards

May 29, 2023 | Behind the Markets (Ad)

Small A.I. Firm Wins $2 Billion in Contracts for Breakthrough "Living Software"

Denver firm proves its possible to use AI to save the lives of soldiers in combat. England, Germany, Japan and Australia have all signed contracts within the past 18 months. Get the name of the stock here >>>

May 25, 2023 | msn.com

Ocean Voyager cruise ship visits Escanaba

May 25, 2023 | finance.yahoo.com

Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

May 23, 2023 | msn.com

Lower Cape Fear LifeCare hosting Camp Voyager to help grieving children

May 20, 2023 | thestreet.com

Embattled Crypto Broker Voyager to Return $1.3 Billion to Customers

May 18, 2023 | finance.yahoo.com

Voyager Therapeutics Presents Robust, Multi-Species Results from Preclinical Studies of IV-Delivered, TRACER™-Generated Novel Capsids at the ASGCT 26th Annual Meeting

May 29, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

May 18, 2023 | americanbankingnews.com

Voyager Therapeutics (NASDAQ:VYGR) vs. Mosaic ImmunoEngineering (OTCMKTS:CPMV) Head to Head Survey

May 17, 2023 | americanbankingnews.com

Sutro Biopharma (NASDAQ:STRO) versus Voyager Therapeutics (NASDAQ:VYGR) Head-To-Head Comparison

May 13, 2023 | americanbankingnews.com

Analysts Offer Predictions for Voyager Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:VYGR)

May 12, 2023 | msn.com

Canaccord Genuity Maintains Voyager Therapeutics (VYGR) Buy Recommendation

May 12, 2023 | americanbankingnews.com

Voyager Therapeutics (NASDAQ:VYGR) Upgraded to Buy at StockNews.com

May 12, 2023 | americanbankingnews.com

Wedbush Weighs in on Voyager Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:VYGR)

May 11, 2023 | americanbankingnews.com

Voyager Therapeutics (NASDAQ:VYGR) Now Covered by Truist Financial

May 9, 2023 | finance.yahoo.com

Voyager Therapeutics (VYGR) Q1 Earnings and Revenues Surpass Estimates

May 8, 2023 | msn.com

Voyager Therapeutics Q1 2023 Earnings Preview

May 8, 2023 | msn.com

Earnings Preview For Voyager Therapeutics

May 7, 2023 | americanbankingnews.com

Voyager Therapeutics (VYGR) to Release Quarterly Earnings on Tuesday

May 6, 2023 | msn.com

How The Voyager Spacecraft Are Still Running After More Than 40 Years

May 5, 2023 | news.yahoo.com

NASA Hack Squeezes More Time Out of Dying Voyager 2 Probe

May 5, 2023 | finance.yahoo.com

Revenues Working Against Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Share Price

May 4, 2023 | finance.yahoo.com

Voyager Therapeutics (VYGR) Surges 11.1%: Is This an Indication of Further Gains?

May 2, 2023 | finance.yahoo.com

Voyager Therapeutics Announces First Quarter 2023 Conference Call and Webcast

April 28, 2023 | msn.com

Voyager 2 has been in space for 45 years. NASA just found a way to keep it alive for another 3, despite it being 12 billion miles from Earth.

April 28, 2023 | msn.com

New power plan will keep Voyager 2 running even longer

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive VYGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VYGR Company Calendar

Last Earnings: 3/07/2023
Today: 5/28/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VYGR
CUSIP: N/A
CIK: 1640266
Web: www.voyagertherapeutics.com
Phone: (857) 259-5340
Fax: N/A
Employees: 101
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $16.00
High Stock Price Forecast: $18.00
Low Stock Price Forecast: $14.00
Forecasted Upside/Downside: +32.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): $2.28
Trailing P/E Ratio: 5.29
Forward P/E Ratio: 11.93
P/E Growth: N/A
Net Income: $-46,410,000.00
Net Margins: -24.21%
Pretax Margin: 52.26%
Return on Equity: 95.18%
Return on Assets: 45.67%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 15.18
Quick Ratio: 15.18

Sales & Book Value

Annual Sales: $40.91 million
Price / Sales: 12.82
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.98 per share
Price / Book: 2.42

Miscellaneous

Outstanding Shares: 43,540,000
Free Float: 33,958,000
Market Cap: $524.66 million
Optionable: Optionable
Beta: 1.12

Key Executives

Alfred W. Sandrock
President, Chief Executive Officer & Director

Robin Swartz
Chief Operating Officer

Peter P. Pfreundschuh
Chief Financial & Accounting Officer

Todd Carter
Chief Scientific Officer

Julie Burek
Vice President-Finance

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VYGR Stock - Frequently Asked Questions

Should I buy or sell Voyager Therapeutics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VYGR shares.
View VYGR analyst ratings or view top-rated stocks.
What is Voyager Therapeutics' stock price forecast for 2023?: 2 analysts have issued twelve-month price targets for Voyager Therapeutics' shares. Their VYGR share price forecasts range from $14.00 to $18.00. On average, they anticipate the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 32.8% from the stock's current price.
View analysts price targets for VYGR or view top-rated stocks among Wall Street analysts.
How have VYGR shares performed in 2023?: Voyager Therapeutics' stock was trading at $6.10 at the beginning of 2023. Since then, VYGR shares have increased by 97.5% and is now trading at $12.05.
View the best growth stocks for 2023 here.
When is Voyager Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our VYGR earnings forecast.
How were Voyager Therapeutics' earnings last quarter?: Voyager Therapeutics, Inc. (NASDAQ:VYGR) posted its quarterly earnings data on Tuesday, March, 7th. The company reported ($0.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by $0.04. The company had revenue of ($1.55) million for the quarter, compared to analysts' expectations of $12.71 million. Voyager Therapeutics had a positive trailing twelve-month return on equity of 95.18% and a negative net margin of 24.21%.
What ETFs hold Voyager Therapeutics' stock?: ETFs with the largest weight of Voyager Therapeutics (NASDAQ:VYGR) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC),

What other stocks do shareholders of Voyager Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT).
What is Voyager Therapeutics' stock symbol?: Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."
Who are Voyager Therapeutics' major shareholders?: Voyager Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include EcoR1 Capital LLC (8.85%), Armistice Capital LLC (8.09%), Price T Rowe Associates Inc. MD (2.07%), BlackRock Inc. (1.89%), Farallon Capital Management LLC (1.83%) and Acadian Asset Management LLC (1.71%). Insiders that own company stock include Alfred Sandrock, Allison Dorval, Andre Turenne, Ecor1 Capital, Llc, Glenn Pierce, Julie Burek, Neurocrine Biosciences Inc, Omar Khwaja, Robert W Hesslein, Robin Swartz, Rock Ventures Iii LP Third and Todd Alfred Carter.
View institutional ownership trends.
How do I buy shares of Voyager Therapeutics?: Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Voyager Therapeutics' stock price today?: One share of VYGR stock can currently be purchased for approximately $12.05.
How much money does Voyager Therapeutics make?: Voyager Therapeutics (NASDAQ:VYGR) has a market capitalization of $524.66 million and generates $40.91 million in revenue each year. The company earns $-46,410,000.00 in net income (profit) each year or $2.28 on an earnings per share basis.
How many employees does Voyager Therapeutics have?: The company employs 101 workers across the globe.
How can I contact Voyager Therapeutics?: Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.voyagertherapeutics.com. The company can be reached via phone at (857) 259-5340 or via email at pcox@vygr.com.

This page (NASDAQ:VYGR) was last updated on 5/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Voyager Therapeutics (VYGR) Stock Forecast, Price & News

Voyager Therapeutics MarketRank™ Forecast

Overall MarketRank™